Experts from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania will be presenting during ASCO’s annual meeting from June 3-7 on the latest advances in solid-tumor targeting and treatment, including for pancreatic and non-small cell lung cancer, innovations in telehealth and text interventions, and strategies to expand diversity and equity.
Experts
Experts from the Abramson Cancer Center and Perelman School of Medicine are available to comment on a wide range of cancer research topics during the meeting in person, by telephone or email. To arrange interviews, please contact Caren Begun at caren.begun@pennmedicine.upenn.edu or 267-408-9196. Follow us on Twitter at @PennCancer, @PennMDForum and @PennMedicine.
New Releases
· Promising Results for Chemo-Immunotherapy Combination Against Pancreatic Cancer, Penn Study Finds
· Initial Surgery May Be Associated with Lower Stroke Risk for Head and Neck Cancer Patients
Other noteworthy abstracts to be presented at ASCO:
· Diversity, Equity and Inclusion in Cancer
o Association between state Medicaid policies and accrual of Black participants to cancer clinical trials (Abstract #1501)
o Racial and ethnic disparities in adherence and reported symptoms during routine collection of patient-reported outcomes (Abstract #6510)
o Variation in telemedicine usage in gynecologic cancer: Are we widening or narrowing disparities? (Abstract #1593)
o Site self-assessments and institutional strategies to advance equity (Abstract #S406)
· Solid Tumors: Pancreatic Cancer
o Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer (Abstract #4010)
o Phase 1, first-in-human study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumor (Abstract #2533)
o A randomized phase Ib/II study of niraparib plus nivolumab or ipilimumab in patients with platinum-sensitive advanced pancreatic cancer (Abstract #4021)
o A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, BRCA or PALB2 related pancreatic cancer who have progressed on rucaparib (Abstract #4131)
o Circulating KRAS variant-specific shedding and association with survival in patients with metastatic pancreatic ductal adenocarcinoma receiving chemoimmunotherapy. (Abstract #2548)
· Non-Small Cell Lung Cancer (NSCLC)
o Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer (Abstract #9022)
o First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC (Abstract #9037)
· Intervention and Prevention
o Long-term effect of machine learning–triggered behavioral nudges on serious illness communication and end-of-life outcomes among patients with cancer: A randomized clinical trial (Abstract #109)
o Association between up-front surgery and risk of stroke in U.S. veterans with oropharyngeal squamous cell carcinoma (Abstract #6057)
o Saving TIME: Accuracy of a text intervention to minimize the time burden of cancer care (Abstract #6527)
o Telehealth weight loss program for breast cancer survivors is feasible and acceptable: Preliminary results of pilot clinical trial (Abstract #TPS1603)
Related Links
Abramson Cancer Center
Perelman School of Medicine
University of Pennsylvania Health System
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.